| HS Code | 837256 |
| Product Name | Bone Proteolytic Enzyme |
| Enzyme Type | Protease (peptidase) |
| Source | Bovine bone extract or microbial fermentation |
| Primary Biological Role | Degrades bone matrix proteins such as collagen and gelatin |
| Optimal Ph Range | 5.5–7.5 |
| Optimal Temperature Range | 37–50°C depending on formulation |
| Substrate Specificity | Collagen, casein, gelatin, and other peptide bonds |
| Cofactors Required | Zinc or calcium ions in metalloprotease variants |
| Known Inhibitors | EDTA, heavy metal ions, and serine protease inhibitors such as PMSF |
| Molecular Weight | 20–35 kDa per typical proteolytic subunit |
| Physical Form | Powder or encapsulated granules |
| Recommended Storage | Cool, dry place away from direct sunlight and high humidity |
| Shelf Life | Typically 2 years from production date when unopened |
| Unit Of Activity | Amount of enzyme liberating 1 µmol of tyrosine per minute under standard assay conditions |
As an accredited Bone Proteolytic Enzyme factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Bone Proteolytic Enzyme, 100 g, sealed amber glass bottle with tamper-evident cap, labeled for laboratory use. |
| Container Loading (20′ FCL) | Bone Proteolytic Enzyme packed in sealed drums, palletized and secured, loaded into 20′ FCL container with moisture protection and proper labeling. |
| Shipping | Bone Proteolytic Enzyme should ship in sealed, moisture-proof containers at controlled temperature (2–8°C) to preserve activity. Use insulated packaging with ice packs, protective outer carton, and hazard documentation. Avoid extreme heat, freezing, or prolonged transit. Include “Handle with Care” labels and ensure compliance with local shipping regulations. |
| Storage | Store Bone Proteolytic Enzyme lyophilized at –20 °C, protected from light and moisture. After reconstitution, aliquot and refrigerate at 4 °C for short-term use, or freeze at –20 °C for longer storage. Avoid repeated freeze-thaw cycles, as they reduce activity. Use sterile, endotoxin-free buffers and handle under clean conditions to maintain stability. |
| Shelf Life | Stable for 12 months at -20°C; avoid repeated freeze-thaw cycles to preserve enzymatic activity. |
Bone pieces discharged from a high-pressure mechanical deboning line still carry 5–12% w/w residual muscle protein and periosteum. A protease application can recover this protein fraction instead of routing it to standard rendering. The enzyme is hydrated in potable water at 10–15°C and introduced into a vacuum tumbler at 0.05–0.20% w/w relative to wet bone mass. The mass is adjusted to pH 6.0–7.0 with food-grade sodium carbonate or citric acid. The tumbler operates at 0.6–0.8 bar vacuum and 8–12 rpm for 60–180 min at 45–55°C. Bone pieces should remain below 3 cm in longest dimension to maximize enzyme contact.
After hydrolysis, the slurry passes through a decanter centrifuge at 3,200–3,600 rpm with differential speed 8–12 rpm. The recovered protein phase contains 12–18% protein depending on raw material and separation settings. The solid bone fraction is discharged for rendering or gelatin extraction. On production lines with high calcium content, enzyme activity can be reduced by calcium phosphate solids suspended in the mixture. These solids abrade seals in peristaltic dosing pumps and settle in the bottom of the tumbler if rotation is interrupted. The slurry should be screened through a 5 mm mesh before centrifugation to protect the decanter scroll. Compliance falls under Regulation (EC) No 853/2004 for mechanically separated meat, with Salmonella monitoring per ISO 6579-1:2017 and protein determination per AOAC 992.15. Residual enzyme activity in the recovered protein must be inactivated before use in emulsified sausage, typically at 70–80°C core temperature during thermal processing.
Demineralized ossein is a collagen-rich intermediate obtained after crushed bone is contacted with 2–4% hydrochloric acid for 72–120 h at ambient temperature. The acid removes calcium phosphate but leaves a fibrillar collagen mass. For peptide production, the ossein is washed until conductivity falls below 2.0 mS/cm. Residual calcium phosphate should remain below 1.0% w/w dry basis; higher ash content shields collagen fibrils from enzyme diffusion and reduces effective proteolytic access.
The hydrolysis step is run at pH 7.0–8.0, 50–60°C, with enzyme charge 0.1–0.5% w/w dry ossein. Reactor configuration is a jacketed, baffled stainless steel vessel with top-entering impeller at 30–60 rpm. Hydrolysis time is 2–6 h, with degree of hydrolysis 5–15% measured by OPA against L-serine. If temperature exceeds 65°C, enzyme denaturation causes a rapid drop in reaction rate within 15–30 min. If pH falls below 6.0, neutral protease activity is suppressed and the product shifts to larger peptide aggregates with poor solubility in cosmetic emulsions.
After hydrolysis, the liquor is clarified by a disk-stack separator at 7,000–9,000 rpm and filtered through 100 µm stainless screens. Ultrafiltration over spiral-wound polyethersulfone membranes with 10 kDa and 3 kDa cut-offs operated at 8–12 bar transmembrane pressure produces a permeate with average molecular weight 1–3 kDa for cosmetic-grade collagen peptides. A heavier 3–5 kDa retentate is dried for nutraceutical use. Final spray drying uses inlet 180–200°C and outlet 80–90°C. The product must comply with Regulation (EC) No 1332/2008 for enzyme use and, where applicable, AOAC 990.26 for hydroxyproline quantification. If the specific bone proteolytic enzyme is not included in the European Union food enzyme register, food use is excluded until authorization is granted.
Bone grist that enters a six-vessel countercurrent extraction battery at particle size 2–4 mm can be pre-treated with a small enzyme charge to raise the proportion of gelatin extracted in the first two vessels. This shifts the production ratio away from later low-grade liquors. The enzyme is applied after acidulation and washing, before the first hot-water extraction. A dose of 0.02–0.08% w/w dry ossein is used at 45–55°C for 30–120 min in a jacketed conveyor or stirred vessel. The treated ossein is then heated to 55°C, followed by extraction at 55–70°C in the first vessel.
The resulting gelatin typically reaches 120–200 Bloom, with viscosity at 6.67% w/w and 60°C in the 3.0–5.5 mPa·s range. When the enzyme dose exceeds 0.10% w/w or contact time exceeds 240 min, gel strength falls below 50 Bloom and the liquor becomes unsuitable for hard-capsule or photographic grade. The risk is a processing-window conflict: higher enzyme doses improve extraction yield but cleave the α-chain fraction responsible for gel network formation. This limits the usable operating range and requires strict batch control.
Gel strength is measured with a texture analyzer using a 12.7 mm diameter plunger on a 6.67% w/w gel matured for 17 h at 10°C, with GMIA Standard Methods, 2019 as the reference test procedure. Extraction vessels are stainless steel with indirect steam heating; temperature control must remain within ±2°C to prevent local overcooking. Published data for this specific configuration is limited; process development trials should include a Bloom-versus-dose gradient from 0.01% to 0.12% w/w dry ossein.
Feed-grade bone hydrolysate production operates under a different economic constraint: protein conversion must be high, but the enzyme cannot be recovered. The reactor feed is bone from Category 3 poultry and porcine material. The bones are crushed to 2–4 mm, mixed with water at 1:1.5 w/v, and heated to 90°C for 20 min to render free fat and reduce microbial load. The slurry is then cooled to 50°C before enzyme addition.
The primary limiting factor is free fat released from bone marrow. At fat levels above 15% w/w in the reactor, the enzyme adsorbs to oil-water interfaces and measurable activity declines by 20–40%. A decanter or tricanter centrifuge before hydrolysis is therefore used when the raw material contains visible marrow fat. Bone particle size above 5 mm also lowers conversion because collagen fibrils are diffusion-limited; target particle size after grinding is 2–4 mm.
Enzyme dose is 0.1–0.5% w/w bone protein, pH 6.5–7.5, temperature 50°C, and residence time 4–8 h in a continuous stirred-tank reactor with top-entering agitator at 30–50 rpm. Degree of hydrolysis reaches 12–20% measured by OPA against L-serine. Mechanical shear also influences conversion. High-speed dispersers creating shear above 200 s⁻¹ can partially unfold the enzyme and lower effective activity. Axial-flow impellers are specified for this reason. At pilot scale, viscosity typically falls from 1,200–2,000 mPa·s to 150–300 mPa·s after 6 h at 50°C. The hydrolysate is dried in a tall-form spray dryer at inlet 180–200°C and outlet 80–90°C. The final meal contains 75–85% protein, <8% moisture, and water activity 0.45–0.55.
Compliance is governed by Regulation (EC) No 1069/2009 for animal by-products and Commission Regulation (EU) No 142/2011 for processed animal proteins. Batch release must confirm absence of Salmonella in 25 g according to ISO 6579-1:2017 and Enterobacteriaceae below 10 CFU/g. If the bone proteolytic enzyme is not listed in the European Union food enzyme register, this feed application remains permissible while food use may be excluded until authorization is granted.
A savoury paste formulation does not treat bone-derived hydrolysate as a single flavour compound. The liquid hydrolysate supplies free amino acids, small peptides, and reducing sugars that participate in Maillard browning during high-temperature processing. Raw bone material is pre-cooked, ground to 2–5 mm, and mixed with water at 1:2 w/w.
Enzyme charge is 0.1–0.4% w/w bone protein, pH 5.5–6.5, temperature 45–55°C, and hydrolysis time 3–6 h. The pH is maintained with citric acid or sodium diacetate. Following hydrolysis, the liquor is heat-inactivated at 85°C for 15 min, passed through a 0.5 mm screen, and concentrated to 35–45 Brix in a vacuum evaporator at 0.2 bar absolute pressure. The dry matter contains 40–50% protein, 15–25% sodium chloride, and 8–15% fat.
Free amino nitrogen by formol titration is 1.0–2.5 g/100 g. This parameter is more meaningful than total protein because it correlates with taste intensity. For process control, a triangle sensory panel is used after dilution to 0.5% w/w protein. Regulatory compliance falls under Regulation (EC) No 1334/2008 for flavouring preparations and Regulation (EC) No 1332/2008 for the enzyme carrier; residual enzyme activity must be absent after thermal inactivation.
The comparative operating windows below summarise the material-specific enzyme dose and endpoint control for six bone-derived streams. The listed ranges are starting conditions for process development and must be confirmed against local raw material variability.
| Parameter | Meat recovery | Ossein peptides | Gelatin pre-treatment | Feed hydrolysate | Savoury base | Hydroxyapatite |
|---|---|---|---|---|---|---|
| Enzyme dose | 0.05–0.20% w/w wet bone | 0.1–0.5% w/w dry ossein | 0.02–0.08% w/w dry ossein | 0.1–0.5% w/w bone protein | 0.1–0.4% w/w bone protein | 0.01–0.05% w/w dry mineral |
| pH | 6.0–7.0 | 7.0–8.0 | 5.5–7.0 | 6.5–7.5 | 5.5–6.5 | 8.0–9.0 |
| Temperature | 45–55°C | 50–60°C | 45–55°C | 50°C | 45–55°C | 45–55°C |
| Residence time | 60–180 min | 2–6 h | 30–120 min | 4–8 h | 3–6 h | 12–24 h |
| Endpoint indicator | Recovered protein 12–18% | DH 5–15% OPA | 120–200 Bloom | DH 12–20% OPA | Free amino N 1.0–2.5 g/100 g | TOC <0.1 wt% |
| Deactivation | 70–80°C core during product cooking | 85°C for 15 min | Extraction heat 55–70°C | 85°C for 15 min or spray dryer heat | 85°C for 15 min | Sintering 800–1,200°C |
Ceramic-grade hydroxyapatite derived from cortical bone is not obtained by simple combustion. Carbonized protein residues left in the mineral matrix create black inclusions and lower the sintering density. After crushing and steam degreasing, 1–2 mm bone mineral is slurried in water at 1:4 w/v.
Enzyme charge is 0.01–0.05% w/w dry mineral, pH 8.0–9.0, temperature 45–55°C, and contact time 12–24 h in a stirred reactor at 30 rpm. The process removes residual collagen and non-collagenous proteins from the mineral crystallites. Cancellous bone hydrolyses faster than cortical bone due to higher porosity; batch blends of mixed skeletal origin therefore require longer residence time and periodic sampling. After hydrolysis, the mineral is washed until conductivity falls below 1.5 mS/cm and dried at 105°C for 4 h.
Sintering is conducted at 800–1,200°C for 2 h with a ramp of 2–5°C/min. Total organic carbon falls below 0.1 wt% when measured by elemental analyzer. The sintered powder is evaluated for phase purity by X-ray diffraction and Ca/P molar ratio 1.67 ± 0.02 by inductively coupled plasma optical emission spectrometry. Applicable standards include ISO 13779-1:2008 for hydroxyapatite ceramics and, for implant-grade powder in some jurisdictions, ASTM F1185-03. Stainless steel contact parts must be 316L grade because residual chloride from demineralization can initiate pitting.
Bone meal designated for fertigation is often too coarse and protein-stable to release nitrogen rapidly in drip systems. Hydrolysate liquor produced with a bone proteolytic enzyme overcomes this limitation. Bone meal with particle size 2–4 mm is mixed with water at 1:3 w/w in a closed reactor.
Enzyme dose is 0.1–0.3% w/w meal, pH 7.5–8.5, temperature 50°C, and residence time 12–24 h. The slurry is passed through a 0.5 mm mesh filter. The liquor contains 5–8% total nitrogen, with free amino acid nitrogen 2.0–3.5% w/w dry matter. The liquor is stabilized with phosphoric acid to pH 4.0–4.5 to inhibit microbial growth during storage.
Compliance for fertilizer markets is governed by Regulation (EU) 2019/1009 for placing fertilising products on the market. Organic input material registers in several national systems require total nitrogen by EN 13654-1 or equivalent and chloride below 2.0% w/w. Published data for this specific configuration is limited; field nitrogen-release curves should be generated before bulk agronomy claims.
Competitive Bone Proteolytic Enzyme prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Bone Proteolytic Enzyme, model BPE-2000, is a lyophilized, chromatographically purified metalloprotease preparation standardized for in vitro processing of allograft bone and demineralized bone matrix manufacturing. The enzyme is derived from Clostridium histolyticum fermentation, purified by size-exclusion and anion-exchange chromatography to reduce clostripain and neutral protease contaminants, and filled as a sterile-filtered bulk powder into 10 mL type I borosilicate vials under dry nitrogen. Each vial contains 100 mg of powder with a residual moisture content of ≤ 3.0% by Karl Fischer titration. The product is not intended for direct patient administration; it is used exclusively as a processing aid during bone tissue decellularization and collagen cleanup after demineralization with 0.6 N hydrochloric acid. Batch documentation includes activity per milligram, collagenase-to-caseinase ratio, endotoxin, bioburden, and residual host cell protein data.
The preparation is shipped under dry ice with a temperature indicator. On receipt, vials are transferred to a −20 °C freezer and allowed to equilibrate for 2 h before reconstitution. Reconstitution is performed by slowly adding 10 mL of sterile-filtered processing buffer to the vial and swirling at 4 °C for 15 min; vortexing is avoided because shear denatures the metalloprotease active site. The resulting solution is clear to faintly opalescent and is stable for 24 h at 2 °C to 8 °C.
Activity for BPE-2000 is measured by the FALGPA hydrolysis method at 25 °C and pH 7.5. One unit is defined as the amount of enzyme that hydrolyzes 1.0 µmol of FALGPA per minute per milligram. For cortical bone processing, the enzyme is reconstituted in a buffer containing 10 mM Tris-HCl, 5 mM CaCl₂, and 0.9% sodium chloride at pH 7.2 to 7.6. Working activity ranges from 0.5 U/mL to 2.5 U/mL, adjusted to bone wet weight and particle size. Calcium is required for metalloprotease activity; the addition of 5 mM EDTA or 1 mM 1,10-phenanthroline lowers catalytic activity to less than 10% of nominal within 30 min. Processing is carried out in a jacketed 316L stainless steel bioreactor with overhead agitation at 120 rpm to 180 rpm. Temperature is maintained at 37 °C ± 1 °C. At temperatures above 45 °C, irreversible denaturation begins; at 20 °C, the reaction rate is approximately 40% of the 37 °C reference. The pH must not exceed 8.5 because prolonged alkaline exposure destabilizes collagen crosslinks and increases enzyme autolysis.
Demineralization with 0.6 N hydrochloric acid at 4 °C is performed before enzyme treatment to expose collagen fibers. The acid is removed by rinsing with cold 0.9% sodium chloride until the pH reaches 7.0 to 7.5. Enzyme digestion then proceeds for 2 h to 8 h depending on particle size and bone source. Human cortical bone from long bone midshaft requires longer digestion than cancellous bone from iliac crest because of higher cortical density and lower surface area per gram. Continuous agitation at 120 rpm to 180 rpm prevents settling of bone particles and ensures uniform enzyme contact. The reaction is stopped by addition of 10 mM EDTA and cooling to 4 °C.
Bone particle size governs digestion efficiency more directly than enzyme lot variation. Cortical bone milled and sieved between 125 µm and 850 µm provides consistent surface area for digestion. Particles above 850 µm require extended exposure beyond 6 h and may retain non-collagenous proteins in the central canal network; particles below 125 µm increase enzyme adsorption losses and reduce the final demineralized bone matrix particle size below the range described in ASTM F2529-13 for osteoinductive bone filler evaluation. In production-scale hammer milling, screen wear has been shown to shift particle size distribution by up to 15%, requiring adjustment of enzyme-to-bone mass ratio from 0.8 U/g to 1.1 U/g wet bone. Residual non-collagenous protein is monitored by hydroxyproline assay for collagen retention and by PicoGreen dsDNA quantification; a target of ≤ 50 ng dsDNA per mg dry bone is used for decellularized bone matrix.
Release specifications follow the test matrix below. Lot-to-lot variance is controlled by monitoring the collagenase-to-caseinase ratio rather than total protein content, because total protein alone does not predict selective non-collagenous protein removal.
| Parameter | Analytical method | Release limit |
|---|---|---|
| Specific collagenase activity | FALGPA hydrolysis, pH 7.5, 25 °C | 200–300 U/mg |
| Collagenase:caseinase ratio | FALGPA and casein hydrolysis assays | 1:3 to 1:8 |
| Residual moisture | Karl Fischer titration | ≤ 3.0% |
| pH after reconstitution | 10 mg/mL in water, 25 °C | 6.8–7.8 |
| Bioburden | ISO 11737-1:2018 | ≤ 10 CFU/vial |
| Endotoxin | USP <85> LAL | ≤ 0.25 EU/mg |
| Cytotoxicity | ISO 10993-5:2009 | No cell lysis at 1:10 extract |
Acceptance of a lot requires conformance to all release limits. Batches outside the collagenase:caseinase ratio of 1:3 to 1:8 are rejected because low ratios under-digest non-collagenous proteins and high ratios over-digest collagen type I, reducing demineralized bone matrix particulate integrity. Stability testing under ISO 13485:2016-controlled conditions supports storage at −20 °C for up to 24 months; accelerated storage at 5 °C for 6 months is used only for transport verification. Published external data for this exact formulation is limited, so facility-specific real-time stability data remains the primary basis for shelf-life assignment.
Residual enzyme must be removed before terminal sterilization. Washing with 0.9% sodium chloride and 70% ethanol reduces enzyme activity to ≤ 0.05 U/mL in the final rinse, but trace adsorption to hydroxyapatite can retain activity. Terminal gamma irradiation at 25 kGy to 35 kGy, validated according to ISO 11137-1:2006, reduces residual activity below detection limits. Published data on gamma-irradiated demineralized bone matrix indicate that BMP-2 recovery loss of 10% to 20% occurs at 25 kGy to 35 kGy when residual moisture is above 3.0%. Lyophilization to ≤ 3.0% residual moisture and irradiation below 4 °C limits free radical-mediated collagen damage. Hydrated bone should not be irradiated after enzyme treatment because aqueous radiolysis crosslinks collagen and reduces osteoinductive potential; this configuration is outside the validated process range.
Process validation according to ISO 11137-1:2006 includes bioburden determination on enzyme-treated bone before packaging. For a bioburden of ≤ 100 CFU per device, a verification dose of 15 kGy to 25 kGy is typically applied; sterilization at 25 kGy to 35 kGy is maintained for product release. Residual enzyme activity is measured by FALGPA assay after irradiation and must be below the detection limit of 0.01 U/mL in the final extract. Enzyme-treated bone that has been lyophilized and irradiated should be evaluated for osteoinductive potential by ASTM F2529-13 implantation in an athymic rat model; published data for this specific enzyme product in that model is limited, so each facility should verify equivalence against a non-enzyme-treated demineralized bone matrix control.
Crude collagenase preparations vary in collagenase-to-neutral protease ratio from 1:1 to 1:20, which complicates reproducible bone digestion. BPE-2000 is purified to a controlled ratio of 1:3 to 1:8. Papain is a cysteine protease that requires cysteine and EDTA for activation; this chelation can remove calcium from bone mineral and alter matrix integrity. Trypsin cleaves at lysine and arginine residues and has low collagenase activity. Pepsin operates at acidic pH and solubilizes collagen rather than retaining a particulate scaffold.
| Enzyme preparation | Optimal pH | Cleavage specificity | Effect on bone collagen | Typical bone processing use |
|---|---|---|---|---|
| BPE-2000 | 6.8–7.8 | Collagenase with controlled neutral protease activity | Retains particulate collagen after limited digestion | Selective non-collagenous protein removal from demineralized bone matrix |
| Crude collagenase | 6.5–8.0 | Variable collagenase, clostripain, neutral protease | May over-digest collagen at high neutral protease ratio | General tissue dissociation |
| Papain | 6.0–7.5 | Broad cysteine protease | Degrades proteoglycans and collagen telopeptides | Cartilage digestion; not suitable for demineralized bone matrix |
| Trypsin | 7.5–8.5 | Lysine/arginine endopeptidase | Fragments bone morphogenetic proteins and collagen after prolonged exposure | Cell harvesting; limited bone cleanup |
| Pepsin | 2.0–4.0 | Acidic endopeptidase | Solubilizes collagen | Collagen extraction; not for matrix retention |
The distinction is most significant during demineralized bone matrix processing because collagen type I must remain crosslinked to retain osteoconductive scaffold properties while non-collagenous proteins are removed. Papain and pepsin cannot maintain this balance. Trypsin may be used as a secondary wash at 0.25% w/v for 4 h at 37 °C, but prolonged exposure reduces BMP-2 concentration in ELISA by 30% to 50% in published studies. BPE-2000 is therefore selected when the target is residual dsDNA below 50 ng/mg and retention of hydroxyproline above 90% of demineralized bone input.
For bone tissue decellularization, the activity of BPE-2000 is maintained in the presence of calcium; papain requires cysteine and EDTA, which can remove calcium from the bone matrix and alter mineral-collagen interactions. Pepsin is commonly used for collagen extraction from tissues because it solubilizes collagen under acidic conditions; this property is incompatible with demineralized bone matrix scaffold retention. The use of BPE-2000 does not eliminate the need for decellularization agents such as 0.1% sodium dodecyl sulfate or 1% Triton X-100, but it reduces the required exposure time and preserves matrix architecture.
Storage requires desiccated conditions at −20 °C or colder. Reconstituted enzyme solution should be used within 24 h when held at 2 °C to 8 °C. Repeated freeze-thaw cycles of reconstituted solution reduce activity by 8% to 12% per cycle. Contact with carbon steel or copper surfaces inhibits metalloprotease activity; only 316L stainless steel, glass, or polypropylene equipment is recommended. The enzyme is incompatible with amine-based buffers above pH 8.5, with strong reducing agents such as dithiothreitol above 1 mM, and with chelating agents. Manufacturing equipment is cleaned with 0.5 M sodium hydroxide followed by 0.1% peracetic acid to inactivate residual proteolytic activity. Cleanliness is verified by FALGPA assay of swab extracts and by biuret protein detection. The enzyme is classified as a processing aid and is not present in the final allograft device above 0.01 U/mL; residual moisture and packaging integrity testing is performed after lyophilization. For bone processing beyond the described particle size and moisture conditions, published data for this specific configuration is limited and validation should be conducted per facility QMS procedures.
